KemPharm (KMPH) Sets New 1-Year Low at $1.15

Share on StockTwits

KemPharm Inc (NASDAQ:KMPH) reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $1.15 and last traded at $1.16, with a volume of 5600 shares trading hands. The stock had previously closed at $1.20.

Separately, ValuEngine downgraded KemPharm from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the company’s stock. KemPharm currently has a consensus rating of “Hold” and an average target price of $10.75.

The firm has a market capitalization of $36.51 million, a price-to-earnings ratio of -0.53 and a beta of 1.63.

KemPharm (NASDAQ:KMPH) last issued its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($0.46) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.46). On average, equities analysts expect that KemPharm Inc will post -1.37 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of KMPH. Vanguard Group Inc. increased its holdings in KemPharm by 9.3% during the 3rd quarter. Vanguard Group Inc. now owns 479,335 shares of the specialty pharmaceutical company’s stock worth $2,301,000 after purchasing an additional 40,700 shares during the period. Vanguard Group Inc increased its holdings in KemPharm by 9.3% during the 3rd quarter. Vanguard Group Inc now owns 479,335 shares of the specialty pharmaceutical company’s stock worth $2,301,000 after purchasing an additional 40,700 shares during the period. Janney Montgomery Scott LLC purchased a new stake in KemPharm during the 4th quarter worth about $44,000. Victory Capital Management Inc. increased its holdings in KemPharm by 48.6% during the 4th quarter. Victory Capital Management Inc. now owns 241,387 shares of the specialty pharmaceutical company’s stock worth $430,000 after purchasing an additional 78,970 shares during the period. Finally, BlackRock Inc. increased its holdings in KemPharm by 25.0% during the 4th quarter. BlackRock Inc. now owns 90,426 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 18,079 shares during the period. Institutional investors own 34.30% of the company’s stock.

TRADEMARK VIOLATION WARNING: “KemPharm (KMPH) Sets New 1-Year Low at $1.15” was published by Equities Focus and is the sole property of of Equities Focus. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.equitiesfocus.com/2019/05/17/kempharm-kmph-sets-new-1-year-low-at-1-15.html.

About KemPharm (NASDAQ:KMPH)

KemPharm, Inc, a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder.

Recommended Story: What are the economic characteristics of a bear market?

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.